

## Total Synthesis of (±)-Butyl Ester of Rosmarinic Acid

Long Jiang HUANG, De Quan YU\*

Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050


**Abstract:** (±)-Butyl ester of rosmarinic acid **1** was synthesized by 5-step reactions through the two key intermediates **2** and **3**, the total yield was 23.9% and 25.1%, respectively.

**Keywords:** Butyl ester of rosmarinic acid, piperonal.

Rosmarinic acid, a well-known natural product firstly isolated from *rosemary* by Scarpati and Oriente in 1958<sup>1</sup>, possesses various kinds of biological activities such as antioxidant<sup>2</sup> and antibacterial<sup>3</sup>. Recently, the synthesis and biological activities of related compounds of rosmarinic acid have received much attention, such as 4, 4'-O-di-β-D-glucopyranosyl rosmarinic acid<sup>4</sup>, methyl ester of rosmarinic acid<sup>5-6</sup> and rabdosiin<sup>7</sup>.

Butyl ester of rosmarinic acid **1** (**Scheme 1**) was isolated from *Isodon oresbius* in 1999<sup>8</sup>. However, there was no report of synthesis and biological activities of this compound. In order to study its biological activities, a new short route for its synthesis was designed (**Scheme 1**).

Scheme 1






**1** R<sub>1</sub>=R<sub>2</sub>=R<sub>3</sub>=R<sub>4</sub>=H

**2** R<sub>1</sub>, R<sub>2</sub>=—CH<sub>2</sub>—, R<sub>3</sub>=R<sub>4</sub>=Bn

**3** R<sub>1</sub>, R<sub>2</sub>=—CH<sub>2</sub>—, R<sub>3</sub>, R<sub>4</sub>=—CH<sub>2</sub>—

\* E-mail: dqyu@imm.ac.cn

**Scheme 2** Synthesis of the intermediate **8****Scheme 3** Synthesis of intermediates **11** and **12****Scheme 4**

Reagents and conditions: a) acetic acid,  $\text{Ac}_2\text{O}$ ,  $\text{NaOAc}$ ,  $120^\circ\text{C}$ , 5 h; b)  $\text{HCl}$ ,  $100^\circ\text{C}$ , 3 h, then  $\text{Zn}/\text{Hg}$ ,  $\text{HCl}$ , 4 h; c)  $\text{H}_2\text{SO}_4$ ,  $\text{CH}_2\text{Cl}_2$ , *n*- $\text{BuOH}$ , 24 h; d)  $\text{K}_2\text{CO}_3$ , ethanol,  $\text{PhCH}_2\text{Cl}$ , reflux, 5 h; e) malonic acid, pyridine, piperidine,  $110^\circ\text{C}$ , 4 h; f) malonic acid, pyridine, piperidine,  $110^\circ\text{C}$ , 3 h; g)  $\text{DCC}$ ,  $\text{DMAP}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-20^\circ\text{C}$ , 10 h; h)  $\text{BBr}_3$ ,  $-78^\circ\text{C}$ , 1.5 h; i)  $\text{BBr}_3$ ,  $-78^\circ\text{C}$ , 3 h.

The key step is the synthesis of the intermediate **8** which was prepared from piperonal **4** as shown in **Scheme 2**. According to classic Erlenmeyer-Plöchl method<sup>9</sup>, piperonal **4** reacted with excess of acetic acid **5** in the presence of anhydrous  $\text{NaOAc}$  in  $\text{Ac}_2\text{O}$  to give azlactone **6** as slight yellow crystals. We adopted “one-pot” procedure in which **6** was refluxed with 3 mol/L hydrochloric acid, and then zinc amalgam was added to give **7**. **8** was obtained by esterification of **7** with *n*- $\text{BuOH}$  in 78% yield.

The other two intermediates **11** and **12** were prepared from 3, 4-dihydroxy benzaldehyde **9** and **4** as shown in **Scheme 3**. **9** was treated with benzyl chloride to afford **10**. **10** or **4** was condensed with malonic acid to yield the intermediate **11** or **12**, respectively.


The title compound **1** was prepared from the intermediates **2** and **3** as shown in **Scheme 4**. Esterification of **8** with **11** and **12** gave **2** and **3**, which were treated with  $\text{BBr}_3$  to give **1**. Benzyl can be more easily removed than methylene in the above

procedure.

The mechanism of formation of **7** from **6** can be postulated as shown in **Scheme 5**. The azlactone **6** was treated with 0.2 mol/L HCl to afford the enamine intermediate **13**. **13** can be easily hydrolyzed with 3 mol/L HCl to afford the intermediate **14**; it was reduced to give the intermediate **7**.

In summary, we have presented a concise approach of preparation of (±)-**1**; the synthetic route from **2** is more facile than from **3**, because it is more amenable to large-scale synthesis. Biological evaluation and asymmetric synthesis of **1** are in progress.

Scheme 5



## References and Notes

1. M. L. Scarpati, G. Oriente, *Ricerca Sci.*, **1958**, 28, 2329.
2. J. H. Chen, C.T. Ho, *J. Agric. Food Chem.*, **1997**, 45, 2374.
3. M. Kuhnt, A. Probstle, H. Rimpier, R. Bauer, M. Heinrich, *Planta Med.*, **1995**, 61, 227.
4. T. Satake, K. Kamiya, Y. Saiki, *et al*, *Chem. Pharm. Bull.*, **1999**, 47, 1444.
5. T. Motoyuki, O. Yasuyuki, *Planta Med.*, **1998**, 64, 555.
6. E. Reimann, H. J. Mass, T. Pflug, *Monatsh. Chem.*, **1997**, 128, 995.
7. D. E. Bogucki, J. L. Charlton, *Can. J. Chem.*, **1997**, 75, 1783.
8. H. Huang, Q.R. Chao, R.X. Tan, *Planta Med.*, **1999**, 65, 92.
9. H. E. Carter, *Org. Reactions*, **1946**, 3, 198.
10. Spectral data of compound **2**:  $^1\text{H NMR}$  (300MHz,  $\text{CDCl}_3$ ,  $\delta$  ppm): 7.61 (d, 1H,  $J=15.9$  Hz, =CH-), 7.49-7.31 (m, 10H, ArH), 7.14 (d, 1H,  $J=2.0$  Hz, ArH), 7.08 (dd, 1H,  $J=8.4$  Hz, 2.0 Hz, ArH), 6.92 (d, 1H,  $J=8.4$  Hz, ArH), 6.78 (d, 1H,  $J=1.4$  Hz, ArH), 6.74 (d, 1H,  $J=8.0$  Hz, ArH), 6.70 (dd, 1H,  $J=8.0$  Hz, 1.4 Hz, ArH), 6.30 (d, 1H,  $J=15.9$  Hz, =CH-), 5.93 (s, 2H,  $\text{OCH}_2\text{O}$ ), 5.30 (t, 1H,  $J=6.6$  Hz, CHO-), 5.20 (s, 2H,  $-\text{OCH}_2\text{Ph}$ ), 5.19 (s, 2H,  $-\text{OCH}_2\text{Ph}$ ), 4.16 (t, 2H,  $J=6.6$  Hz,  $-\text{OCH}_2-$ ), 3.12 (t, 2H,  $J=6.6$  Hz,  $\text{CH}_2\text{Ar}$ ), 1.65-1.58 (m, 2H,  $\text{CH}_2$ ), 1.41-1.28 (m, 2H,  $\text{CH}_2$ ), 0.92 (t, 3H,  $J=7.2$  Hz,  $\text{CH}_3$ ); IR (KBr,  $\text{cm}^{-1}$ ): 1743, 1716, 1634, 1596; EI-MS:  $m/z$  608 ( $\text{M}^+$ , 0.2), 91 (100); HREI-MS:  $m/z$  608.2457 (calcd. for  $\text{C}_{37}\text{H}_{36}\text{O}_8$ , 608.2410).
11. Spectral data of compound **3**:  $^1\text{H NMR}$  (300MHz,  $\text{CDCl}_3$ ,  $\delta$  ppm): 7.60 (d, 1H,  $J=15.9$  Hz, =CH-), 7.03-6.68 (m, 6H, ArH), 6.28 (d, 1H,  $J=15.9$  Hz, =CH-), 5.98 (s, 2H,  $\text{OCH}_2\text{O}$ ), 5.91 (s, 2H,  $\text{OCH}_2\text{O}$ ), 5.27 (t, 1H,  $J=6.6$  Hz, CHO-), 4.13 (t, 2H,  $J=6.4$  Hz,  $\text{CH}_2\text{O}$ ), 3.11 (d, 2H,  $J=6.6$  Hz,  $\text{CH}_2\text{Ar}$ ), 1.67-1.52 (m, 2H,  $\text{CH}_2$ ), 1.38-1.24 (m, 2H,  $\text{CH}_2$ ), 0.90 (t, 3H,  $J=7.2$  Hz,  $\text{CH}_3$ ); EI-MS:  $m/z$  440 ( $\text{M}^+$ , 1), 248 (89), 192 (100), 135 (45); IR (KBr,  $\text{cm}^{-1}$ ): 1743, 1716, 1629, 1601. HREI-MS:  $m/z$  440.1484 (calcd. for  $\text{C}_{24}\text{H}_{24}\text{O}_8$ , 440.1471).
12. Spectral data of compound **1**:  $^1\text{H NMR}$  (300MHz,  $\text{DMSO}-d_6$ ,  $\delta$  ppm): 7.48 (d, 1H,  $J=15.9$  Hz, H-7), 7.06 (d, 1H,  $J=1.8$  Hz, H-2), 7.04 (dd, 1H,  $J=7.8$  Hz, 1.8 Hz, H-6), 6.77 (d, 1H,  $J=7.8$  Hz, H-5), 6.65 (d, 1H,  $J=1.8$  Hz, H-2'), 6.63 (d, 1H,  $J=7.8$  Hz, H-5'), 6.49 (dd, 1H,  $J=7.8$  Hz,

1.8 Hz, H-6'), 6.26 (d, 1H, J=15.9 Hz, H-8), 5.08 (t, 1H, J=6.6 Hz, H-8'), 4.03 (t, 2H, J=6.0 Hz, H-1''), 2.95 (d, 2H, J=6.6 Hz, H-7'), 1.52-1.38 (m, 2H, H-2''), 1.36-1.28 (m, 2H, H-3''), 0.84 (t, 3H, J=7.2 Hz, H-4''); <sup>13</sup>CNMR (75MHz, DMSO-d<sub>6</sub>, δ ppm): 169.5 (C-9'), 165.9 (C-9), 148.6 (C-4), 146.3 (C-3), 145.5 (C-7), 144.9 (C-3'), 144.1 (C-4'), 125.6 (C-1'), 125.3 (C-1), 121.7 (C-6), 120.1 (C-6'), 116.7 (C-2'), 115.7 (C-5), 115.4 (C-5'), 114.9 (C-2), 112.9 (C-8), 72.9 (C-8'), 64.4 (C-1''), 36.2 (C-7'), 30.0 (C-2''), 18.4 (C-3''), 13.5 (C-4''); IR (KBr, cm<sup>-1</sup>): 3379, 1716, 1604; FAB-MS: *m/z* 417 (M<sup>+</sup>+1, 0.1), 163 (100); HRFAB-MS: *m/z* 417.1534 [M+H]<sup>+</sup> (calcd. for C<sub>22</sub>H<sub>25</sub>O<sub>8</sub>, 417.1549).

Received 12 July, 2004